Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.

Trial Details

NCT ID
NCT02870244
Phase
PHASE1
Sponsor
Loyola University
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Escalating Doses
Locations (sample)
  • Maywood, Illinois, United States|41.8792,-87.84312

Key Eligibility Criteria

  • Patients must have a diagnosis of metastatic melanoma which is evaluable either clinically or radiologically.
  • Patients must be 18 years of age or older.
  • Patients must consent to be in the study and must have signed and dated an approved consent form, which conforms to federal and institutional guide…
  • Patients must have a performance status (PS) of 0 or 1 ECOG PS scale.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →